taurolidine/citrate/heparin (Pending FDA Approval)

Brand and Other Names:Defencath
Sections

Dosing & Uses

Dosage Forms & Strengths

taurolidine/citrate/heparin

injection, catheter lock solution

  • (1.35%/3.5%/1000 units) per mL

Catheter-related Bloodstream Infections

Pending FDA approval for prevention of catheter-related bloodstream infections (CRBSIs) in patients with end-stage renal disease (ESRD) receiving hemodialysis through a central venous catheter

Next:

Pharmacology

Mechanism of Action

Taurolidine: Amino acid with broad antimicrobial activity against gram-positive and gram-negative bacteria, as well as mycobacteria; also elicits antifungal effects

Citrate: Exerts anticoagulant effect by chelating ionized calcium, which is a cofactor in the clotting cascade

Heparin: In low doses, it inactivates Factor Xa and inhibits conversion of prothrombin to thrombin

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.